Jefferies analyst Roger Song maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...
BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...
Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $32.87 which represents a slight increase of $0.22 or 0.67% from the prior close of $32.65. The stock opened at $32.87 and ...
Viking Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -34.83%. The profit margin, also known as the revenue ratio or gross profit ...
Executives at Amgen made the case for MariTide's differentiation, while Merck's CEO contended Keytruda's coming loss of exclusivity can be managed.
Viking Therapeutics, Inc. has a 1 year low of $18.14 and a 1 year high of $99.41. The firm has a market capitalization of $4.74 billion, a PE ratio of -45.73 and a beta of 0.95. Get Viking ...
Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.
Viking Therapeutics (PRNewsfoto/Viking Therapeutics ... of this compound into later-stage development," said Brian Lian, chief executive officer of Viking Therapeutics. "Prior 28-day Phase ...
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the ...
13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics ... development," said Brian Lian, chief executive ...